News

You are here

Novosanis will present its VAX-ID™ device platform during BioJapan
Novosanis considers Japan as an important market due to its innovative vision towards healthcare and diagnostics.
Prostate cancer is the most common male cancer, with around 400,000 new cases every year in Europe.

Pages